H. Robert Superko, M.D., presented data on genetic polymorphisms (SNPs) and cardiovascular disease. The boosters of comparative effectiveness research are pushing government policy away from personalized medicine. After listening to Superko’s presentation I am convinced that this is the wrong direction to go.
The KIF6 variant predicts statin responsiveness. In the PROVE IT trial, NNT for intensive statin benefit was 10 in carriers, 125 in non-carriers!
A variant of the LPA gene is a powerful predictor of aspirin responsiveness (NNT 37 vs. 400!).
More on this soon.